Skip to Content
Merck
CN
All Photos(1)

Documents

F0175000

Flucytosine

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing

Synonym(s):
5-Fluorocytosine, 4-amino-5-fluoro-2(1H)-pyrimidinone, Flucytosine
Empirical Formula (Hill Notation):
C4H4FN3O
CAS Number:
Molecular Weight:
129.09
Beilstein:
127285
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

flucytosine

manufacturer/tradename

EDQM

mp

298-300 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC1=NC(=O)NC=C1F

InChI

1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)

InChI key

XRECTZIEBJDKEO-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Flucytosine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Nucleoside analog that has antifungal activities. 5-FC is deaminated by cytosine deaminase to product 5-fluorouracil, resulting in RNA miscoding. 5-Fluorocytosine inhibits DNA and RNA synthesis and interferes with ribosomal protein synthesis.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Repr. 2

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nese Karaaslan Biyikli et al.
Pediatric nephrology (Berlin, Germany), 19(7), 801-804 (2004-06-03)
Bilateral fungal obstruction of the renal collecting system is rare in infancy. Treatment options include medical or surgical procedures. Reports of successful medical treatment with liposomal amphotericin B have been published but the duration of treatment is controversial. We report
R Patel
Mayo Clinic proceedings, 73(12), 1205-1225 (1998-12-30)
Traditionally, amphotericin B has been the cornerstone of antifungal treatment. Toxicity, however, is a major dose-limiting factor of amphotericin B deoxycholate. Nevertheless, it continues to have a major role in the treatment of deep-seated mycotic infections. Recently, less nephrotic lipid
A Polak
Annales de biologie clinique, 45(6), 669-672 (1987-01-01)
The antimycotic and pharmacological properties of 5-fluorocytosine are presented. Especially the aspect of good gastrointestinal absorption, elimination by the kidney, unwanted side effects and appearance of primary and secondary resistance are discussed. The indication of 5 FC monotherapy or combination
B Gerson
Clinics in laboratory medicine, 7(3), 541-544 (1987-09-01)
Monitoring of flucytosine (5-FC) concentration in serum is of great importance. It may be anticipated that demand for this service will increase in the near future, because this drug is used in situations involving immunocompromised patients, including those afflicted with
I Marinová et al.
Chemotherapy, 40(4), 287-289 (1994-07-01)
A case of Rhodotorula fungemia in a 13-year-old boy after neurosurgery successfully treated with miconazole and 5-flucytosine is reported. Intravascular catheter insertion, broad-spectrum anti-miocrobials, surgery, and immunosuppression are the main risk factors for fungemia.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service